Findings from pivotal nipocalimab Phase 3 study in a broad antibody[...]
Findings from pivotal nipocalimab Phase 3 study in a broad antibody[...]
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
04/29/2024 | Press release | Archived content
Please select the service you want to use:
Smartlinks | Xometry Inc. | News | Finance | Security Markets | Security Markets | Company News | Top Company News | Corporate Debt | Shareholders | Shareholder Meeting | Proxy Statements | Information Technology | Software | Securities Issuers | Software Companies | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2025 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact